Switch theme
Sign up to access all valuation multiples
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
2011
1.8K+
LTM Revenue $1.5B
LTM EBITDA $392M
$4.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alkermes has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $392M.
In the most recent fiscal year, Alkermes achieved revenue of $1.6B and an EBITDA of $495M.
Alkermes expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alkermes valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $392M | XXX | $495M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $332M | XXX | $421M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $296M | XXX | $367M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alkermes's stock price is $31.
Alkermes has current market cap of $5.0B, and EV of $4.2B.
See Alkermes trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.2B | $5.0B | XXX | XXX | XXX | XXX | $2.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alkermes has market cap of $5.0B and EV of $4.2B.
Alkermes's trades at 2.7x EV/Revenue multiple, and 8.6x EV/EBITDA.
Equity research analysts estimate Alkermes's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkermes has a P/E ratio of 17.0x.
See valuation multiples for Alkermes and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 10.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.0x | XXX | 13.8x | XXX | XXX | XXX |
| EV/FCF | 11.4x | XXX | 10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlkermes's last 12 month revenue growth is -5%
Alkermes's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Alkermes's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alkermes's rule of X is 13% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alkermes and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | -23% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 13% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkermes acquired XXX companies to date.
Last acquisition by Alkermes was XXXXXXXX, XXXXX XXXXX XXXXXX . Alkermes acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alkermes founded? | Alkermes was founded in 2011. |
| Where is Alkermes headquartered? | Alkermes is headquartered in United States of America. |
| How many employees does Alkermes have? | As of today, Alkermes has 1.8K+ employees. |
| Who is the CEO of Alkermes? | Alkermes's CEO is Mr. Richard F. Pops. |
| Is Alkermes publicy listed? | Yes, Alkermes is a public company listed on NAS. |
| What is the stock symbol of Alkermes? | Alkermes trades under ALKS ticker. |
| When did Alkermes go public? | Alkermes went public in 1991. |
| Who are competitors of Alkermes? | Similar companies to Alkermes include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alkermes? | Alkermes's current market cap is $5.0B |
| What is the current revenue of Alkermes? | Alkermes's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Alkermes? | Alkermes revenue growth (NTM/LTM) is -5%. |
| What is the current EV/Revenue multiple of Alkermes? | Current revenue multiple of Alkermes is 2.9x. |
| Is Alkermes profitable? | Yes, Alkermes is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alkermes? | Alkermes's last 12 months EBITDA is $392M. |
| What is Alkermes's EBITDA margin? | Alkermes's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Alkermes? | Current EBITDA multiple of Alkermes is 10.8x. |
| What is the current FCF of Alkermes? | Alkermes's last 12 months FCF is $373M. |
| What is Alkermes's FCF margin? | Alkermes's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of Alkermes? | Current FCF multiple of Alkermes is 11.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
